Summit Therapeutics Inc.
SMMT
Positions held
Your positionsSMMT isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Summit Therapeutics Inc. operates in a competitive biotechnology sector with a strong focus on innovative therapies, which positions it well for future growth as demand for advanced healthcare solutions increases.
- The company has a market capitalization of approximately $13.81 billion, indicating significant investor interest and potential for growth.
- With a recommendation of 'buy' and a target mean price of $29.75, analysts are optimistic about the stock's future performance.
- Summit Therapeutics faces challenges with no revenue reported in recent quarters, which raises concerns about its financial sustainability and ability to fund operations.
- The company reported a net income loss of $215.7 million in Q2 2026, continuing a trend of negative earnings over multiple quarters.
- Summit's current ratio stands at 6.96, indicating high liquidity, but the negative free cash flow of approximately $139.68 million suggests ongoing financial strain.
Fundamentals
| Market cap | $13.70B | Enterprise value | $13.03B | Trailing P/E | — | Forward P/E | -15.07 |
| PEG | — | Price / book | 21.62 | Beta | -1.52 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -1.9% | ROA | -101.6% | Debt / equity | 0.03 |
| Current ratio | 6.96 | Free cash flow | -$139.68M | Analyst recommendation | buy | Mean target | $29.77 |
| 52w high | $29.23 | 52w low | $12.07 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$216M | -$189M | -$219M | -$232M | -$566M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$220M | -$195M | -$225M | -$234M | -$568M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.7M | — |
| Op margin | — | — | — | -9024.3% | — |
| Net income | -$1.1B | -$221M | -$615M | -$78.8M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$1.1B | -$211M | -$88.7M | -$63.6M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Goldman Sachs Says China Biotech Is Where Big Pharma Is Shopping Now
2026-10-06 · AstraZeneca CEO Pascal Soriot on Summit ivonescimab combos
2026-10-05 · SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos
2026-10-05 · Summit Therapeutics Secures $2 Billion Investment From AstraZeneca
2026-10-05 · AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
2026-10-02 · Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration
2026-10-02 · Sector Update: Healthcare Stocks Steady Late Afternoon
2026-10-02 · AstraZeneca Stocks Moves Lower as Datroway Combination Enters Phase 3
2026-10-02 · Sector Update: Healthcare Stocks Softer in Afternoon Trading
2026-10-02 · Sector Update: Healthcare
2026-10-02 · AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact
2026-10-02 · Summit Teams Up With Daiichi Sankyo, AstraZeneca For Cancer Therapy Trial – CEO Calls It An ‘Important Expansion’
Price (daily)
Full chart · RSI · MACD · patterns